Optical biopsy of rectal scars after cancer treatment
Part of Cancer, Digestive system clinical trials.
This trial tests a targeted “optical biopsy” (using a special light-based exam to sample tissue) to better assess rectal scars after standard chemotherapy and radiation before surgery. It may help surgeons choose the most appropriate way to operate on rectal cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 79 years old
- Your health for anesthesia is rated as mild to moderate (ASA I, II, or III)
- You have locally advanced rectal cancer
- You finished the usual chemotherapy plus radiation treatment before surgery
- Your doctors expect you will have rectal surgery
- You can sign an informed consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at a specific type of rectal surgery after you’ve already finished chemo-radiation, aiming to remove the tumor while trying to preserve the anal sphincter (muscle control). It’s meant for people whose cancer can be safely operated on and who don’t have spread to distant organs.
This study tests a newer kind of imaging (ultrasound plus light-based measurements) to help doctors tell rectal cancer apart from other tissue during surgery. You may be able to take part if you’re having surgery for rectal cancer and the tumor is close enough to the anus.
This study looks at how rectal cancer responds to the usual chemotherapy and radiation given before surgery. It aims to learn if certain molecular features of your tumor can predict how well it responds to treatment.
This trial checks whether taking small samples from the full thickness of rectal tissue can accurately confirm that rectal cancer has fully responded to chemotherapy and/or radiation. It may help doctors decide the best next step if no tumor is seen after treatment.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This study looks at whether it’s practical and safe to treat certain rectal cancers without surgery. You may be offered non-surgical (“neoadjuvant”) treatment and close follow-up to see how well it works in a rural setting.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.